Close Menu

NEW YORK – Trovagene has begun enrolling patients into the Phase Ib/II trial of onvansertib evaluating the investigational PLK1 inhibitor as a treatment for KRAS-mutated metastatic colorectal cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.